BAX
Price
$24.69
Change
+$0.29 (+1.19%)
Updated
Aug 29 closing price
Capitalization
12.68B
61 days until earnings call
NVST
Price
$21.18
Change
-$0.07 (-0.33%)
Updated
Aug 29 closing price
Capitalization
3.52B
60 days until earnings call
Interact to see
Advertisement

BAX vs NVST

Header iconBAX vs NVST Comparison
Open Charts BAX vs NVSTBanner chart's image
Baxter International
Price$24.69
Change+$0.29 (+1.19%)
Volume$4.05M
Capitalization12.68B
Envista Holdings
Price$21.18
Change-$0.07 (-0.33%)
Volume$1.04M
Capitalization3.52B
BAX vs NVST Comparison Chart in %
Loading...
BAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BAX vs. NVST commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongBuy and NVST is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (BAX: $24.69 vs. NVST: $21.18)
Brand notoriety: BAX and NVST are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BAX: 56% vs. NVST: 49%
Market capitalization -- BAX: $12.53B vs. NVST: $3.52B
BAX [@Pharmaceuticals: Other] is valued at $12.53B. NVST’s [@Pharmaceuticals: Other] market capitalization is $3.52B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $169.67B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 2 FA rating(s) are green whileNVST’s FA Score has 0 green FA rating(s).

  • BAX’s FA Score: 2 green, 3 red.
  • NVST’s FA Score: 0 green, 5 red.
According to our system of comparison, BAX is a better buy in the long-term than NVST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 5 TA indicator(s) are bullish while NVST’s TA Score has 5 bullish TA indicator(s).

  • BAX’s TA Score: 5 bullish, 3 bearish.
  • NVST’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both BAX and NVST are a good buy in the short-term.

Price Growth

BAX (@Pharmaceuticals: Other) experienced а +1.32% price change this week, while NVST (@Pharmaceuticals: Other) price change was -2.49% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.93%. For the same industry, the average monthly price growth was +6.00%, and the average quarterly price growth was +26.47%.

Reported Earning Dates

BAX is expected to report earnings on Oct 30, 2025.

NVST is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.93% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BAX($12.7B) has a higher market cap than NVST($3.52B). BAX has higher P/E ratio than NVST: BAX (87.85) vs NVST (66.19). NVST YTD gains are higher at: 9.798 vs. BAX (-13.843). BAX has higher annual earnings (EBITDA): 1.04B vs. NVST (303M). BAX has more cash in the bank: 1.8B vs. NVST (1.11B). NVST has less debt than BAX: NVST (1.6B) vs BAX (10.3B). BAX has higher revenues than NVST: BAX (10.9B) vs NVST (2.55B).
BAXNVSTBAX / NVST
Capitalization12.7B3.52B361%
EBITDA1.04B303M342%
Gain YTD-13.8439.798-141%
P/E Ratio87.8566.19133%
Revenue10.9B2.55B427%
Total Cash1.8B1.11B162%
Total Debt10.3B1.6B645%
FUNDAMENTALS RATINGS
BAX vs NVST: Fundamental Ratings
BAX
NVST
OUTLOOK RATING
1..100
127
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9290
PRICE GROWTH RATING
1..100
6548
P/E GROWTH RATING
1..100
3147
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BAX's Valuation (20) in the Medical Specialties industry is somewhat better than the same rating for NVST (74) in the null industry. This means that BAX’s stock grew somewhat faster than NVST’s over the last 12 months.

BAX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVST (100) in the null industry. This means that BAX’s stock grew similarly to NVST’s over the last 12 months.

NVST's SMR Rating (90) in the null industry is in the same range as BAX (92) in the Medical Specialties industry. This means that NVST’s stock grew similarly to BAX’s over the last 12 months.

NVST's Price Growth Rating (48) in the null industry is in the same range as BAX (65) in the Medical Specialties industry. This means that NVST’s stock grew similarly to BAX’s over the last 12 months.

BAX's P/E Growth Rating (31) in the Medical Specialties industry is in the same range as NVST (47) in the null industry. This means that BAX’s stock grew similarly to NVST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXNVST
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 6 days ago
51%
Bullish Trend 3 days ago
66%
Declines
ODDS (%)
Bearish Trend 10 days ago
61%
Bearish Trend 16 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
BAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ADBG11.330.13
+1.20%
Leverage Shares 2X Long ADBE Daily ETF
GAA31.530.07
+0.21%
Cambria Global Asset Allocation ETF
PTEC39.56N/A
N/A
Global X PropTech ETF
OMFS43.16-0.23
-0.53%
Invesco Russell 2000® Dynamic Mltfct ETF
BBEM60.08-0.33
-0.55%
JPMorgan BetaBuilders Emerging Mkt EqETF

BAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BAX has been closely correlated with ALGN. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BAX jumps, then ALGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BAX
1D Price
Change %
BAX100%
+1.90%
ALGN - BAX
68%
Closely correlated
+0.59%
LUNG - BAX
53%
Loosely correlated
-2.84%
STE - BAX
51%
Loosely correlated
+0.12%
SYK - BAX
51%
Loosely correlated
+0.45%
SOLV - BAX
50%
Loosely correlated
+0.59%
More

NVST and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVST has been loosely correlated with BIO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NVST jumps, then BIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVST
1D Price
Change %
NVST100%
-0.33%
BIO - NVST
57%
Loosely correlated
+1.43%
A - NVST
55%
Loosely correlated
+0.56%
ALGN - NVST
53%
Loosely correlated
+0.59%
XRAY - NVST
53%
Loosely correlated
-0.14%
MTD - NVST
52%
Loosely correlated
+1.40%
More